Los Angeles, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Immune Thrombocytopenia Clinical Trial Analysis and Pipeline Assessment
Immune Thrombocytopenia Pipeline Appears Robust and Rich with the Active Presence of over 30+ Major Pharma Players including Argenx, UCB Pharma, Amgen, Takeda, Octapharma USA, Principia Biopharma, HanAll Biopharma, and BMS.
DelveInsight’s “Immune Thrombocytopenia (ITP) Pipeline Report 2020” provides detailed coverage of the pipeline (under development) landscape and the growth prospects under ITP therapeutic domain. The report provides a kaleidoscopic view of the therapeutic advancements underway equipped with data from multiple sources with complete Immune Thrombocytopenia clinical trial analysis.
Some of the highlights of the Immune thrombocytopenia pipeline report are:
- The report covers 30+ companies and 30+ pipeline drugs in the Immune thrombocytopenia pipeline landscape.
- The Immune thrombocytopenia pipeline report covers therapies broadly segmented on the basis of drug type as mono- and combination-therapies, various routes of administrations, different stages of clinical development, types of molecules, types of the mechanism of actions, and various types of targets on which the drugs act.
- The expected launch of upcoming therapies including Efgartigimod (Argenx), Rozanolixizumab (UCB pharma), TAK-079 (Takeda), HL161 (HanAll Biopharma) among various others is anticipated to strengthen the Immune thrombocytopenia pipeline.
- Rozanolixizumab has received orphan drug designation by the USFDA on 30 April 2018 and by the European Commission on 11 January 2019 for its use in the ITP market.
- In November 2020, Rilzabrutinib received Fast Track Designation (FTD) by USFDA and is currently under a Phase 3 study for ITP. Rilzabrutinib received an orphan drug designation from the FDA for the treatment of ITP in October 2018.
- Pharmaceutical companies that are investigating their candidates in the late-stage of development are Argenx, UCB Pharma, HanAll Biopharma among others.
- The present Immune thrombocytopenia treatment market comprises TPO-RA therapies including Nplate (Amgen), Promacta (Novartis), and Doptelet (Dova Pharmaceuticals) in the US and Europe as approved ones. Besides, drugs like Takecab (Takeda), and Nexium capsules (AstraZeneca) are also approved in Japan.
- Patent expiries of already approved drugs such as Nplate and Promacta will give the freeway to generics and biosimilars in the ITP market.
Request sample to know more about the report highlights @ Immune thrombocytopenia pipeline
Immune thrombocytopenia is a bleeding disorder usually without anemia or leukopenia and characterized by the improper functioning or destruction of platelets. It was formerly known as idiopathic thrombocytopenic purpura.
Immune thrombocytopenia treatments
The present treatment market offers corticosteroids, intravenous immunoglobulin (IVIg), and intravenous anti-D immunoglobulin (the latter only for non-splenectomized Rhesus-D positive patients) as first-line treatment. For relapse ITP cases or in patients who fail to respond to first-line treatment, Splenectomy is considered. It is known to provide long term efficacy in around 60% of the ITP cases. Second-line drug therapies include high dose dexamethasone or methylprednisolone, high-dose IVIg or anti-D Ig, vinca alkaloids, and danazol, the immunosuppressants cyclophosphamide, azathioprine, and cyclosporine or mycophenolate mofetil, and the anti-CD-20 monoclonal antibody rituximab.
However, present treatment approaches only provide means to manage platelet count so as to prevent excess bleeding rather than correcting the illness. However, a horde of pharma companies is running clinical trials investigating novel therapeutic agents to correct the illness. Although there have been few well-designed randomized trials targeted at reducing chronic ITP in adults as well as children; however, further prospective trials, adequate long-term follow-up are expected to unfold a better picture of the drugs and therapies, their efficiency, safety, adherence, tolerability, and cost-effectiveness.
Know more about the pipeline therapies and changing landscape @ Immune thrombocytopenia drug pipeline
Key Players Boosting ITP Pipeline
- Argenx
- HanAll Biopharma
- Eris Lifesciences
- Momenta Pharmaceuticals
- Taiho Pharmaceutical
- Takeda
- UCB Pharma
- Immunomedics
- Oscotech
- Bioverativ, a Sanofi company
- Pfizer
- Protalex
ITP Pipeline Therapies
- Efgartigimod
- Rozanolixizumab
- TAK-079
- HL161
- Romiplostim biosimilar
- M254
- PRN1008
- HMPL-523
- SKI-O-703
- HBM9161
- BIVV009
- PRTX-001
Get a detailed picture of key pharmaceutical companies advancing the Immune thrombocytopenia pipeline @ Immune thrombocytopenia key pharma players
Immune thrombocytopenia pipeline report segmentation
Phases of clinical development
- Late-stage products (Phase III and Phase II/III)
- Mid-stage products (Phase II and Phase II/III)
- Early-stage products (Phase I/II and Phase I) along with the details of Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Oral
- Parenteral
- Subcutaneous
- Topical
Molecule types
- Gene therapies
- Small molecule
- Vaccines
- Polymers
- Peptides
- Monoclonal antibodies
Product Type
- Mono
- Combination
- Mono/Combination
Request for Webex demo @ Immune thrombocytopenia pipeline insights 2020
Table of contents
| 1 | Introduction |
| 2 | Executive Summary |
| 3 | Immune Thrombocytopenia: Overview |
| 4 | Pipeline Therapeutics |
| 5 | Immune thrombocytopenia Therapeutic Assessment |
| 6 | Immune thrombocytopenia – DelveInsight’s Analytical Perspective |
| 7 | In-depth Commercial Assessment |
| 8 | Immune thrombocytopenia Collaboration Deals |
| 9 | Late Stage Products (Phase III) |
| 10 | Mid Stage Products (Phase II) |
| 11 | Early Stage Products (Phase I) |
| 12 | Pre-clinical and Discovery Stage Products |
| 13 | Inactive Products |
| 14 | Immune thrombocytopenia Key Companies |
| 15 | Immune thrombocytopenia Key Products |
| 16 | Immune thrombocytopenia- Unmet Needs |
| 17 | Immune thrombocytopenia- Market Drivers and Barriers |
| 18 | Immune thrombocytopenia- Future Perspectives and Conclusion |
| 19 | Immune thrombocytopenia Analyst Views |
| 20 | Immune thrombocytopenia Key Companies |
| 21 | Appendix |
Scope of the report
- Geography Coverage: Global.
- Comprehensive coverage of key companies and their detailed insights into their drug candidates.
- Major collaborations between pharmaceutical companies and academia.
- Ongoing clinical trials segmented into different phases.
- Recent happenings on the research front and news front in the ITP market.
Key questions answered
- How many companies are developing Immune Thrombocytopenia drugs?
- How many Immune Thrombocytopenia drugs are developed by each company?
- How many emerging drugs are in mid-stage and late-stage development for the treatment of Immune Thrombocytopenia?
- What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Immune Thrombocytopenia therapeutics?
- What are the recent trends, drug types, and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Immune Thrombocytopenia and their status?
- What are the key designations that have been granted to emerging drugs?
Got queries? Ask our experts @ Immune thrombocytopenia drug pipeline
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.